Shattuck Labs, Inc. (STTK) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$5.89

From 52W high−25.43%

Volume7.36M

Market cap$603.18M

P/E (TTM)—

P/S (TTM)603.2x

Div yield—

Key dataSep 18, 2026

Open

$5.89

From 52W high

−25.43%

Volume

7.36M

Market cap

$603.18M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.2x

P/E (TTM)

—

RSI (14)

34.8

MomentumView details →

1D Return

+2.74%

YTD Return

+64.11%

SummaryUpdated Jun 1, 2026

Shattuck Labs, Inc. (NASDAQ:STTK) is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas. The company went public in October 2020 and focuses on developing innovative therapeutics for cancer and autoimmune diseases. Shattuck Labs specializes in creating fusion proteins that can simultaneously target multiple pathways in the immune system, representing a novel approach to cancer immunotherapy. The company is currently advancing its lead drug candidate through Phase 1 clinical trials while developing additional programs through its proprietary platform technology.

Ask drillr about Shattuck Labs, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.2x

EV/Sales

542.6x

P/S (TTM)

603.2x

P/B (TTM)

2.9x

ProfitabilityView details →

Gross Margin

−750.90%

Net Margin

−5256.80%

EBITDA Margin

−4845.40%

ROE (TTM)

−24.90%

ROA (TTM)

−23.82%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−66.63%

EPS YoY

+57.85%

FCF YoY

+26.28%

Revenue CAGR 3Y

+15.32%

EPS CAGR 3Y

+53.02%

EBITDA YoY

+19.19%

MomentumView details →

1D Return

+2.74%

YTD Return

+64.11%

1Y Return

+162.72%

RSI (14)

34.8

vs 50D SMA

−14.47%

vs 200D SMA

+5.67%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

27.59x

Quick Ratio

27.59x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.12

EPS Surprise

3.28%

Beats (12Q)

10/12

Next Q EPS Est

−$0.11

Avg Surprise (4Q)

7.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.00M

Net Income (TTM)

−52.57M

Op. CF (TTM)

−41.03M

Next earningsNov 10, 2026 →

Latest newsMore news →

Shattuck Labs reported financial results for Q2 2026, with zero revenue, a net loss of $15.2 million, and diluted EPS of -$0.12.41d ago

Shattuck Labs elected Taylor Schreiber, Helen M. Boudreau, and Clay Siegall as Class III directors, effective May 28, 2026.111d ago

Similar companies

CorMedix Inc.CRMD CytomX Therapeutics, Inc.CTMX Phathom Pharmaceuticals, Inc.PHAT 3D Medicines Inc.01244.HK AgomAb Therapeutics N.V. American Depositary SharesAGMB Bright Minds Biosciences Inc.DRUG Find similar companies →

Latest newsMore news →

Shattuck Labs reported financial results for Q2 2026, with zero revenue, a net loss of $15.2 million, and diluted EPS of -$0.12.41d ago Shattuck Labs elected Taylor Schreiber, Helen M. Boudreau, and Clay Siegall as Class III directors, effective May 28, 2026.111d ago